Abstract
The development of gene technology has opened unprecedented new perspectives in the understanding as well as the treatment of medical disorders. Although molecular techniques and genetic engineering were introduced into the pain field with a significant delay, as compared with other areas in neuroscience, they are now regarded as the prime methods for addressing mechanisms which underly cellular and network changes causing chronic pain. It is now not only possible to delete or to overexpress pain-associated molecules, but also feasible to bring about these changes selectively in distinct anatomical compartments of the pain pathway. At the very forefront is the method of conditional gene deletion using the Cre-loxP system in transgenic mice. This remains by far the most robust and clean approach for selective modification of gene expression. Some limitations of the Cre-loxP system in mice are now being overcome by novel approaches such as RNA interference. Moreover, RNA- and DNA viruses are emerging as excellent tools for delivering genes or deleting them in distinct regions in the pain pathway. Not only do these methodologies offer means for rapidly testing a large number of candidate molecules for their potential functions in pain, but they also allow, for the first time, a possibility of moving gene technology out of the laboratory straight to the bedside of chronically pain-afflicted patients.
Preview
Unable to display preview. Download preview PDF.
General Citations
Alexandra Joyner. Gene Targeting: A Practical Approach (2nd ed). Oxford University Press.
Burton EA, Fink DJ, Glorioso JC. 2005. Replica-tiondefective genomic HSV gene therapy vectors: design, production and CNS applications. Curr Opin Mol Ther, 7(4): 326–336.
Dorsett Y, Tuschl T. 2004. siRNAs: Applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov, 3(4): 318–329.
During M J, Young D, Baer K, Lawlor P Klugmann M. 2003. Development and optimization of adeno-associated virus vector transfer into the central nervous system. Methods Mol Med, 76: 221–236.
Ehrengruber MU. 2002. Alphaviral vectors for gene transfer into neurons. Mol Neurobiol, 26(2–3): 183–201.
Janson CG, During MJ. 2001. Viral vectors as part of an integrated functional genomics program. Genomics, 78(1–2): 3–6.
Lariviere WR, Chesler EJ, Mogil JS. 2001. Transgenic studies of pain and analgesia: mutation or background genotype? J Pharmacol Exp Ther, 297(2): 467–473.
Mansuy IM, Bujard H. 2000. Tetracycline-regulated gene expression in the brain. Curr Opin Neurobiol, 10(5): 593–596.
Meister G, Tuschl T. 2004. Mechanisms of gene silencing by double-stranded RNA. Nature, 431(7006): 343–349.
Nagy A. 2000. Cre recombinase: the universal reagent for genome tailoring. Genesis, 26: 99–109.
Discovery Citations Region-specific Cre mouse lines relevant to pain analysis
Agarwal N, Offermanns S, Kuner R. 2004. Conditio-nal gene targeting in neurons of the dorsal root ganglia and trigeminal ganglia. Genesis, 38(3): 122–129
Gelman DM, Noain D, Avale ME, Otero V, Low MJ, Rubinstein M. 2003. Transgenic mice engineered to target Cre/loxP-mediated DNA recombination into catecholaminergic neurons. Genesis, 36(4): 196–202.
Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, Tronche F, Kellendonk C, Gau D, Kapfhammer J, Otto C, Schmid W, Schutz G. 2002. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet, 31(1): 47–54.
Stirling LC, Forlani G, Baker MD, Wood JN, Matth-ews EA, Dickenson AH, Nassar MA. 2005. Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain, 113(1–2): 27–36.
Region-specific gene expression using the tTA system
Mayford M, Bach M E, Huang Y Y, Wang L, Hawkins R D, Kandel E R. 1996. Control of memory for mation through regulated expression of a CaMK II transgene. Science, 274: 1678–1683.
RNAi technology (including application in pain research)
Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J. 2004. siRNA relieves chronic neuropathic pain. Nucleic Acids Research, 32(5): e49.
Viral-mediated gene delivery in pain research
Eaton MJ, Blits B, Ruitenberg MJ, Verhaagen J, Oudega M. 2002. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Therapy, 9(20): 1387–1395.
Chattopadhyay M, Goss J, Wolfe D, Goins WC, Huang S, Glorioso JC, Mata M, Fink DJ. 2004. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain, 127(Pt 4): 929–939.
South SM, Kohno T, Kaspar BK, Hegarty D, Vissel B, Drake CT, Ohata M, Jenab S, Sailer AW, Malkmus S, Masuyama T, Horner P, Bogulavsky J, Gage FH, Yaksh TL, Woolf CJ, Heinemann SF, Inturrisi C. 2003. A conditional deletion of the NR1 subunit of the NMD A receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. JNeurosci, 23: 5031–5040.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Higher Education Press
About this chapter
Cite this chapter
Kuner, R. (2007). Genetic Approaches for the Study of Pain. In: Zhuo, M. (eds) Molecular Pain. Springer, New York, NY. https://doi.org/10.1007/978-0-387-75269-3_18
Download citation
DOI: https://doi.org/10.1007/978-0-387-75269-3_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-75268-6
Online ISBN: 978-0-387-75269-3